BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI)
CUSIP: 09075P105
Q3 2018 13F Holders as of 30 Sep 2018
- Type / Class
- Equity / Common Stock, par value $0.001
- Shares outstanding
- 26,011,000
- Total 13F shares
- 3,251,790
- Share change
- -471,775
- Total reported value
- $24,996,000
- Price per share
- $7.66
- Number of holders
- 17
- Value change
- -$3,807,303
- Number of buys
- 9
- Number of sells
- 11
Quarterly Holders Quick Answers
What is CUSIP 09075P105?
CUSIP 09075P105 identifies BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 09075P105:
Top shareholders of BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
6.4%
|
1,666,666
|
$15,333,000 | — | 30 Jun 2018 | |
| Artemis Investment Management LLP |
13F
|
Company |
4.8%
|
1,238,495
|
$11,351,000 | — | 30 Jun 2018 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.2%
|
300,798
|
$2,767,000 | — | 30 Jun 2018 | |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM |
13F
|
Company |
1.1%
|
298,400
|
$2,745,000 | — | 30 Jun 2018 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.25%
|
65,809
|
$605,000 | — | 30 Jun 2018 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.18%
|
45,796
|
$421,000 | — | 30 Jun 2018 | |
| Prudence Asset Management Ltd |
13F
|
Company |
0.12%
|
30,000
|
$272,000 | — | 30 Jun 2018 | |
| Marshall Wace North America L.P. |
13F
|
Company |
0.07%
|
18,907
|
$174,000 | — | 30 Jun 2018 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.06%
|
14,957
|
$137,000 | — | 30 Jun 2018 | |
| DC Investments Management, LLC |
13F
|
Company |
0.05%
|
13,259
|
$122,000 | — | 30 Jun 2018 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.04%
|
10,620
|
$98,000 | — | 30 Jun 2018 | |
| Laurion Capital Management LP |
13F
|
Company |
0.04%
|
10,000
|
$92,000 | — | 30 Jun 2018 | |
| UBS Group AG |
13F
|
Company |
0.01%
|
3,196
|
$29,000 | — | 30 Jun 2018 | |
| C M BIDWELL & ASSOCIATES LTD |
13F
|
Company |
0.01%
|
2,500
|
$23,000 | — | 30 Jun 2018 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.01%
|
2,026
|
$19,000 | — | 30 Jun 2018 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
1,237
|
$11,000 | — | 30 Jun 2018 | |
| Point72 Hong Kong Ltd |
13F
|
Company |
0%
|
448
|
$4,000 | — | 30 Jun 2018 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
300
|
$3,000 | — | 30 Jun 2018 | |
| RWA WEALTH PARTNERS, LLC |
13F
|
Company |
0%
|
151
|
$1,000 | — | 30 Jun 2018 |
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) as of Q3 2018
As of 30 Sep 2018,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,251,790 shares.
The largest 10 holders included
FMR LLC, Artemis Investment Management LLP, CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM, Vanguard Group Inc, Point72 Asset Management, L.P., Squarepoint Ops LLC, BlackRock Inc., Creative Planning, MORGAN STANLEY, and UBS Group AG.
This page lists
17
institutional shareholders reporting positions in this security
for the Q3 2018 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2018 vs Q2 2018 Across Filers
Q2 2018 holders
19
Q3 2018 holders
17
Holder diff
-2
| Investor | Q2 2018 Shares | Q3 2018 Shares | Share Diff | Share Chg % | Q2 2018 Value $ | Q3 2018 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.